Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 10/20 | 0.47 |
| ▸ | CTSS | P25774 | 9/20 | 0.47 |
| ▸ | CTSL | P07711 | 3/20 | 0.43 |
| ▸ | CTSB | P07858 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | HRH2 | P25021 | 2/20 | 0.40 |
| ▸ | HRH1 | P35367 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL316667 | 1.00 | CTSK (0.47) | CTSKCTSSCTSLCTSBCYP1A2 | |
| SCHEMBL522884 | 0.90 | CTSK (0.47) | CTSKCTSSHRH2HRH1 | |
| SCHEMBL522883 | 0.90 | CTSK (0.47) | CTSKCTSSHRH2HRH1 | |
| SCHEMBL3332100 | 0.84 | CYP1A2 (0.44) | CTSLCYP1A2CYP2C9CYP2C19HTT | |
| SCHEMBL3332096 | 0.84 | CYP1A2 (0.44) | CTSLCYP1A2CYP2C9CYP2C19HTT | |
| SCHEMBL952832 | 0.81 | SMN1; SMN2 (0.47) | CTSKCTSLCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL952834 | 0.81 | SMN1; SMN2 (0.47) | CTSKCTSLCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL20594751 | 0.81 | CTSS (0.57) | CTSKCTSSCTSLCTSBCYP1A2 | |
| SCHEMBL2585308 | 0.80 | P2RY12 (0.50) | CYP1A2CYP2C9CYP2C19HTT | |
| SCHEMBL2585311 | 0.80 | P2RY12 (0.50) | CYP1A2CYP2C9CYP2C19HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2081903-B1 | 2-AMINOCARBONYL-PYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2014-05-07 | — | — | EP | disclosed |
| US-8093250-B2 | 2-aminocarbonyl-pyridine derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-01-10 | — | — | US | disclosed |
| US-20100035895-A1 | 2-AMINOCARBONYL-PYRIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035895-A1 | 2-AMINOCARBONYL-PYRIDINE DERIVATIVES | P2RY12, P2RY2, P2RY1 | CTSK 4261/4885CTSS 4393/4885CTSL 3275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.